Circulating tumor cells (CTCs) were added to the arsenal of clinical testing in 2004 for three cancer types: metastatic breast, prostate, and colorectal cancer. CTCs were found to be an independent prognostic indicator of survival for these three diseases. Multiple enrichment/isolation strategies have been developed and numerous assay applications have been performed using both single and pooled captured/enriched CTCs. We have reviewed the isolation techniques and touched on many analyses. The true utility of a CTC is that it acts as a "silent" predictor of metastatic disease. The mere presence of a single CTC is an indication that disease has spread from the primary site. Comments and suggestions have been set forth for CTCs and cell-free DNA to be used as a screening panel for the early detection of disease recurrence and metastatic spread, providing the opportunity for early intervention with curative intent to treat metastatic disease.
Introduction
The description of circulating tumor cells (CTCs) in the peripheral blood of cancer patients dates back to Ashworth's observations in 1869 1 . The isolation and detection of CTCs in the blood has proven to be technically challenging. CTCs are rare compared to other circulating cells 2 , and there is a lack of unique, welldefined universal surface targets amongst all malignant cell types. To complicate the issue, there is the possibility of a change in surface targets dependent on CTC maturation status, e.g. during epithelial to mesenchymal transition (EMT) 3 . In spite of these challenges, researchers have developed a variety of techniques to capture and identify these cells. CellSearch TM (Menarini, Bologna, Italy) is generally thought of as the "gold standard" and remains the only analytically valid and FDA-cleared platform for prognostic use in breast, prostate, and colorectal cancers. Studies by Allard, Cristofanilli, de Bono, and Cohen established enumeration of CTCs as an independent prognostic factor for survival [4] [5] [6] [7] [8] [9] [10] [11] . In addition, it has been shown that serial evaluations of CTCs during treatments show fluctuations and can serve as a biomarker of response to monitor therapies [12] [13] [14] [15] [16] . However, even though physicians do not treat patients based on the presence of CTCs, there is utility in these cells. CTCs have been labeled as a "liquid biopsy", a source of tumor cells from the blood when conventional tissue biopsies are not attainable, which can be employed to phenotypically characterize the tumor and as a DNA/RNA source for genomic interrogation.
We will briefly summarize examples of various techniques to obtain CTCs and then review the analyses of CTCs. In conclusion, we will comment on CTCs as a "silent predictor".
Isolation techniques
Isolation strategies can fall into two broad categories: 1) immunobased capture/depletion that relies on immunological recognition of unique biomarkers (i.e. EpCAM) and 2) techniques that exploit a physical property of the CTCs. Although these various techniques are utilized for the enrichment of CTCs, the classification of the captured cells as epithelial cancer cells relies on immuno-staining to confirm whether the isolated cells are tumor or normal circulating cellular components.
Immuno-based capture/depletion for enrichment and/or immuno-labeling for identification CellSearch TM enriches for CTCs in whole blood by first labeling with an avidin-biotin anti-EpCAM-ferrofluid complex followed by magnetic capture. CTCs are then differentially stained using DAPI to identify nucleated cells, epithelial structural cytokeratins (CK8, CK18, and CK19), and anti-CD45 to differentiate CTCs from circulating white blood cells (WBCs).
The LiquidBiopsy platform (Cynvenio Biosystems, Westlake Village, CA, USA) enriches for CTCs by initially differentially immuno-staining with a DAPI, CK, anti-CD45, anti-EpCAMbiotin cocktail and then introduces avidin-ferrofluid for magnetic immobilization. CTCs with a CTC/WBC ratio of 1% or more are analyzed with next-gene sequencing (NGS). The LiquidBiopsy platform isolates circulating cell-free DNA (ccfDNA) from the plasma, DNA from whole blood to evaluate somatic mutations, and CTC-derived DNA (ctcDNA) 27 . This product can be directly used for molecular interrogation, flow cytometry, or further selection procedures.
The OncoQuick (Greiner Bio-One International GmbH, Germany) system precedes density centrifugation with size-based filtration to isolate CTCs 28 , employing RT-PCR for detection. AccuCyte (RareCyte, Seattle, WA, USA) combines density centrifugation with immuno-staining and whole-exome sequencing to identify CTCs 29 .
The unique electrical properties of CTCs are exploited by using a di-electrophoretic (DEP) field flow technology following a pre-CTC enrichment in the DEPArray (Menarini Silicon Biosystems, Castel Maggiore, Italy) 30 and ApoStream (ApoCell, Houston, TX, USA) instruments 31, 32 .
Dr Huang's lab at Pennsylvania State University demonstrated that an acoustic, on-chip flow cytometer (taSSAW) was able to separate CTCs from blood in flow 33 . Acoustic separation exploits both size and compressibility differences to separate cell types 34 .
Analysis of isolated circulating tumor cells
CTCs show a wide range of phenotypic and genetic variations dependent on their primary tumor source. CTCs are, therefore, a very attractive source to use for differential diagnoses, prognoses, therapeutic target selections, and therapeutic response monitoring.
Immunophenotyping of circulating tumor cells
Immunophenotyping of CTCs can reveal the biology of tumor origin for patients with "carcinoma of unknown primaries" (CUP). For example, multiplexed immunofluorescence staining of isolated CTCs with CK7, CK8, CK20, thyroid transcription factor 1 (TTF-1), estrogen receptor (ER), or prostate-specific antigen (PSA) could reveal the tissue of origin as the lung, differentiating it from breast, colorectal, and prostate cancer. CTCs provide a non-invasive diagnostic blood test as an adjunct to a tissue biopsy 35 . Individual CTCs, CTC clusters, EMT-CTCs, and cancer-associated macrophage-like cells (CAMLs) all give support for metastatic disease. These observed variations and the immunophenotyping of CTCs have added prognostic value, e.g. the CTC cluster size and number are associated with lower overall survival in patients with breast, pancreatic, or prostate cancer 36, 37 . CAMLs express epithelial, monocytic, and endothelial protein markers and represent engulfed CTCs. The significance of CAMLs to prognosis has not been defined; however, CAMLs may be evidence of early disease when identified in otherwise healthy individuals, thus serving as a screening tool 23, 38 . The limitation of conventional immunophenotyping of CTCs is their rarity. In order to analyze multiple biomarkers in a single CTC, techniques have been developed using borohydride quenching on photoactivatable fluorophores of fluorescently stained CTCs, enabling "sequential re-staining" with additional biomarkers without the destruction of epitopes. Up to 10 markers have been shown to be feasible with re-stainings on a single CTC Fluorescence in situ hybridization (FISH) is superior to protein assessment of HER-2 status in predicting response to HER-2-targeted immunotherapy in breast cancer patients, potentially identifying patients who may benefit from treatment adjustments 45 . When FISH HER-2 on CTCs was compared to HER-2 status on the primary tumors, a 93% concordance in HER-2 status was observed 46 .
Genotyping of circulating tumor cells versus solid tumor
CTCs represent the dividing cells within the solid tumor mass, and single-cell sequencing has begun to unravel key questions in cancer invasion, metastasis, and therapy resistance that have been difficult to address with bulk tumor measurement 47 . CTC mutations represent predictive and prognostic biomarkers and identify potential therapeutic targets.
Investigating whether the DNA mutational status of CTCs can represent that of the originating tumor is of great clinical importance. The mutational status of KRAS, BRAF, CD133, and Plastin3 (PLS3) was probed in CTCs from patients with colorectal cancer and was compared with that of the originating tumor from the same patient. Discordance between the original tumor and CTCs for KRAS, BRAF, CD133 rs3130, CD133 rs2286455, and PLS3 rs6643869 mutations was 5.77%, 3.85%, 11.54%, 7.69%, and 11.54%, respectively. This study supports the notion that the DNA mutational status of CTCs is a non-invasive, specific biomarker diagnostic tool 48 . . NGS of CTC genomes has also identified distinct copy-number aberrations in patients with chemo-sensitive and chemo-refractory small-cell lung cancer (SCLC) 51 . In additional studies, NGS analysis of single, pooled, and clusters of CTCs from six patients with metastatic breast cancer (MBC) revealed mutational heterogeneity in PIK3CA, TP53, RB1, and ERBB2 genes, mutations matching those revealed in tissue NGS. In six single CTCs isolated from one MBC patient, one CTC had TP53 R110 delC, one CTC had TP53 R110 delG, and four single CTCs had the wild-type p53. Only a TP53 R110 delC was obtained from 14 pooled CTCs isolated from the same patient. In the tumor breast tissue from the same patient, only TP53 R110 delG mutation was detected. Single CTC and cluster analysis from another MBC patient showed mutational heterogeneity in TP53, PIK3CA, and two ERBB2 mutations [52] [53] [54] . Such heterogeneity could be one explanation for the lack of response to targeted therapies.
Additional functional analyses of circulating tumor cells
Viable CTCs would allow functional studies on the biology of CTCs, the identification of druggable therapeutic targets or pathways, and in vitro and in vivo drug testing. Analyses reported include direct single-cell lipido-metabolomics of CTCs from a neuroblastoma patient's blood analyzed with live single-cell mass spectrometry 55 ; in addition, microtubule bundling used as a marker of efficient taxane drug-target engagement has been visualized in CTCs isolated from castrate-resistant prostate cancer patients receiving taxane chemotherapy with docetaxel and paclitaxel, which has allowed the ex vivo examination of how sensitive CTCs are to taxane therapy. In one experiment, testing revealed an unperturbed microtubule network following docetaxel treatment; however, the addition of paclitaxel resulted in microtubule bundling, revealing a sensitivity to that drug 56 , cell invasion assays using CTCs from ovarian cancer patients have been shown to be predictive of shorter disease-free survival 57 , and epithelial immunospot (EPISPOT) assays have shown the capability of detecting proteins secreted/ released/shed from single CTCs to distinguish between apoptotic and viable CTCs 58 .
Culture of circulating tumor cells
Culturing CTCs in vitro/in vivo could facilitate drug development. Owing to the rarity of CTCs, it is necessary to culture CTCs and establish cell lines. Most isolated CTCs are not capable of dividing in situ. However, viable CTCs have been shown to proliferate in cell culture in response to stem cell growth factors such as epidermal growth factor (EGF) and fibroblast growth factor 2 (FGF2). The first permanent cell line came from CTCs of a patient with colon cancer: CTC-MCC-41 59 . CTCs isolated from 14 of 19 early stage lung cancer patients have been successfully expanded with a microfluidic in situ capture and grown in a three-dimensional co-culture model. These CTCs were verified to carry identical mutations from the primary tumors 60 . Viable CTCs have also been isolated from the blood of a patient with CUP using a microfluidic flexible micro spring array (FMSA) device 61 .
Circulating tumor-cell-derived xenografts
The histological, transcriptomic, proteomic, and genomic similarities and comparable treatment responses between the originating tumors and patient-derived xenografts (PDXs) make PDXs useful models in research 62 . CTC-derived xenografts (CDXs) are alternatives to PDXs when tumors are inaccessible or difficult to biopsy. CDXs from patients with either chemo-sensitive or chemorefractory SCLC have been shown to recapitulate the drugsensitivity patterns, genotyping, and clinical outcomes 63 , and combinational treatment was shown to suppress tumor growth in a CDX from a chemo-refractory SCLC patient 64 . Other CDX models have been cited.
Comments and questions
What have we learned about CTCs? If a CTC or multiple CTCs are present then the cancer is metastatic by definition-it has traveled from its primary source. CTCs serve as a "silent" predictor of metastatic disease, and this is probably the most underutilized but informative usage of CTCs overall. But all cancers are not equal in their ability to present as a CTC. In a disease-to-disease comparison when reviewing the percentage of patients exhibiting CTCs, CTCs are seen in a higher percentage of breast and prostate cancer patients than in colorectal cancer patients The physiologic and morphologic differences between various organs could predetermine a CTC's ability to enter the circulation. In addition, some cells are more structurally "sound" than others and can withstand the forces in the circulatory system, while others will fragment. The vascularization within various tumors is not equal. The existence and type of lymphatic tissue, organized nodes versus diffuse lymphatic tissue found throughout the gastrointestinal tract or lungs, could greatly influence a tumor's metastatic potential. These are all areas which require further investigation to uncover differences in CTC presence/absence in various cancers.
The continued research in the field of CTCs has shown these cells to be a valuable tumor source: "a liquid biopsy". And because the body is always in a "cleaning mode" with the flux of lymphatic fluid over and through the tissues depositing waste into the blood circulation for disposal, that waste is the supplier of CTCs along with "cell-free circulating plasma"-also termed "a liquid biopsy"-and cell-free DNA (cfDNA) [66] [67] [68] . Do CTCs and cfDNA give the same information? No, cfDNA will present in all malignancies in both primary and metastatic disease once a detectable level is reached. However, cfDNA alone cannot predict progression from primary to metastatic disease. cfDNA can be used to detect minimal residual disease following initial treatment for curative intent (chemotherapy/surgery) and to detect recurrence 69 . However, recurrence at the primary site or the spread to metastatic sites cannot be differentiated by cfDNA alone. An increase in cfDNA would be reflective of tumor burden but not where the tumor is, if it cannot be visualized on a scan.
Can CTCs and cfDNA be combined in such a manner to aid in the cure of metastatic disease? Yes, and used in combination and including a control of whole blood to detect somatic mutations, CTCs-the "silent" predictor of metastatic disease-and cfDNA can serve to monitor the progression of primary disease to a metastatic state and this combination can be used for every tumor type [66] [67] [68] [69] [70] [71] . Collection algorithms for plasma and CTC determinations can be created with the first screening performed prior to any initial treatment. If CTCs are found (even a CTC level of 1), this is indicative of metastatic disease. Following curative treatment, cfDNA analysis should be employed to determine if there is residual disease and then continue cfDNA testing as surveillance. When increases are seen, the addition of CTCs to cfDNA can be made. cfDNA and CTCs will present significantly earlier than recurrent tumor visibility seen by CT/MRI scans. The advantages of CTCs and cfDNA include 1. they are a cost effective alternative to repeat negative scans, 2. they provide biological information to identify targetable mutations, and 3. they are superior to the routine cancer biomarkers currently followed 70, 71 . Clinical trials need to be conducted to validate CTC/cfDNA evaluations following primary disease curative strategies with treatment induction again at the time of CTC/cfDNA emergence to determine overall survival elongations.
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